147 related articles for article (PubMed ID: 11742477)
1. Rituximab: mechanisms and applications.
Johnson PW; Glennie MJ
Br J Cancer; 2001 Nov; 85(11):1619-23. PubMed ID: 11742477
[No Abstract] [Full Text] [Related]
2. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
Tobinai K
Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
[TBL] [Abstract][Full Text] [Related]
3. [Rituximab in the treatment of B-cell non-Hodgkin lymphoma].
Mitrović Z; Aurer I
Lijec Vjesn; 2006; 128(1-2):36-42. PubMed ID: 16640226
[TBL] [Abstract][Full Text] [Related]
4. Re: Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.
Bennett M; Yegena S; Dave HP; Schechter GP
Hematol Oncol; 2008 Jun; 26(2):114. PubMed ID: 18271062
[No Abstract] [Full Text] [Related]
5. Optimizing rituximab in B-cell lymphoma.
Horning SJ
J Clin Oncol; 2005 Feb; 23(6):1056-8. PubMed ID: 15657408
[No Abstract] [Full Text] [Related]
6. Rituximab in diffuse large B-cell lymphoma.
Coiffier B
Clin Adv Hematol Oncol; 2004 Mar; 2(3):156-7. PubMed ID: 16166943
[No Abstract] [Full Text] [Related]
7. The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation.
Impellizeri JA; Howell K; McKeever KP; Crow SE
Vet J; 2006 May; 171(3):556-8. PubMed ID: 16624725
[TBL] [Abstract][Full Text] [Related]
8. Improvement of peripheral nervous system manifestations of B-cell non-Hodgkin's lymphoma after rituximab therapy.
Briani C; Zambello R; Cavallaro T; Ferrari S; Lucchetta M; Pollanz S; Grisold W
J Peripher Nerv Syst; 2009 Jun; 14(2):146-8. PubMed ID: 19691537
[No Abstract] [Full Text] [Related]
9. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K
Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous B-cell lymphoma treated with rituximab infusions.
Schneider LA
Acta Derm Venereol; 2006; 86(6):550-1. PubMed ID: 17106608
[No Abstract] [Full Text] [Related]
11. Rituximab for intraocular lymphoma.
Itty S; Pulido JS
Retina; 2009 Feb; 29(2):129-32. PubMed ID: 19202422
[No Abstract] [Full Text] [Related]
12. The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence.
Attias D; Weitzman S
Curr Opin Pediatr; 2008 Feb; 20(1):17-22. PubMed ID: 18197034
[TBL] [Abstract][Full Text] [Related]
13. Current status of rituximab maintenance therapy.
Vose JM
Clin Adv Hematol Oncol; 2007 Dec; 5(12):968-9,1006. PubMed ID: 18277958
[No Abstract] [Full Text] [Related]
14. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
Ratanatharathorn V; Pavletic S; Uberti JP
Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
[TBL] [Abstract][Full Text] [Related]
15. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
[TBL] [Abstract][Full Text] [Related]
16. Use of biological response modifiers to enhance the action of Rituximab.
Taylor RP
Leuk Res; 2005 Jun; 29(6):599-600. PubMed ID: 15863194
[No Abstract] [Full Text] [Related]
17. Rituximab for the treatment of diffuse large B-cell lymphomas.
Held G; Pöschel V; Pfreundschuh M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
[TBL] [Abstract][Full Text] [Related]
18. Pediatric primary cutaneous marginal zone B-cell lymphoma treated with intralesional rituximab.
Park MY; Jung HJ; Park JE; Kim YC
Eur J Dermatol; 2010; 20(4):533-4. PubMed ID: 20542839
[No Abstract] [Full Text] [Related]
19. [Low-grade cutaneous B-cell lymphoma: Failure of intralesional rituximab (Mabthera)].
Abasq C; Duval-Modeste AB; Courville P; Joly P
Ann Dermatol Venereol; 2008; 135(6-7):509-11. PubMed ID: 18598807
[No Abstract] [Full Text] [Related]
20. Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis.
Takao T; Kobayashi Y; Kuroda J; Omoto A; Nishimura T; Kamitsuji Y; Fukiya E; Nakamura C; Kimura S; Yoshikawa T
Am J Hematol; 2004 Dec; 77(4):419-20. PubMed ID: 15551361
[No Abstract] [Full Text] [Related]
[Next] [New Search]
